A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Jun 2018
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 06 Jun 2018 Planned End Date changed from 18 Feb 2024 to 12 Jun 2024.
- 06 Jun 2018 Planned initiation date changed from 2 Mar 2018 to 25 Jun 2018.
- 25 Jan 2018 New trial record